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Terms and deﬁnitions: Amyloid ﬁbrils, protein aggregates having a cross-b
structure and other characeristics, e.g., speciﬁc dye-binding; Amyloidosis, any
pathological state associated with the formation of extracellular amyloid deposits;
Functional amyloid, an amyloid structure found to have a beneﬁcial function in
living systems; Oligomers, clusters of small or large numbers of protein or peptide
molecules without a ﬁbrillar appearance; Protein deposition disease, any patho-
logical state with the formation of intracellular or extracellular protein deposits;
Protein misfolding, the conversion of a protein into a structure that differs from its
native state
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Amyloid formation by the neuropancreatic hormone, islet amyloid polypeptide (IAPP or amylin),
one of the most amyloidogenic sequences known, leads to islet amyloidosis in type 2 diabetes
and to islet transplant failure. Under normal conditions, IAPP plays a role in the maintenance of
energy homeostasis by regulating several metabolic parameters, such as satiety, blood glucose lev-
els, adiposity and body weight. The mechanisms of IAPP amyloid formation, the nature of IAPP toxic
species and the cellular pathways that lead to pancreatic b-cell toxicity are not well characterized.
Several mechanisms of toxicity, including receptor and non-receptor-mediated events, have been
proposed. Analogs of IAPP have been approved for the treatment of diabetes and are under investi-
gation for the treatment of obesity.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
Amyloids are partially ordered, ﬁbrillar, protein aggregates that
are rich in b-sheet structure. Amyloid formation has been impli-
cated in more than 30 different human disorders including such
debilitating diseases as Alzheimer’s disease (AD), Parkinson’s dis-
ease (PD) and type 2 diabetes (T2D) (Table 1). Amyloid formation
is not restricted to in vivo pathological conditions; a large number
of proteins that do not form amyloid in vivo can be induced to do
so in vitro under non-physiological conditions [1–4]. Amyloid can,
in some cases, be functional and beneﬁcial [4]. In this review, we
focus on amyloid formation by islet amyloid polypeptide (IAPP,
amylin), a neuropancreatic hormone that forms pancreatic islet
amyloid in T2D and contributes to b-cell dysfunction and death.
We ﬁrst outline the biosynthesis of IAPP and describe its normal
physiological roles. We then discuss IAPP amyloid formation, withemphasis on potential mechanisms of toxicity, drawing analogy to
proteins and physiological consequences documented in other
amyloidosis diseases, which have not yet been characterized for is-
let amyloid. We conclude with a brief description of the clinical
applications of IAPP analogs.
The kinetics of amyloid formation is complex and displays a sig-
moidal proﬁle with three observable phases. The initial steps of
aggregation, which lead to formation of an active seed, occur in
the lag phase and represent the rate limiting process. In this phase,
monomers oligomerize and convert into species that nucleate an
exponential ﬁbril growth phase. Fibrils elongate by addition of
peptide to their ends. Secondary nucleation that involves the cata-
lyst of ﬁbril formation from existing ﬁbrils also occurs. This may in-
volve breakage of existing ﬁbrils to increase the concentration of
free ends, or the templating of new ﬁbrils on the surface of existing
ones. Finally, a steady state is reached where soluble peptide is at
equilibrium with amyloid ﬁbrils. Off-pathway steps leading to
amorphous aggregates also occur. Amyloid formation can be accel-
erated by the addition of small amounts of preformed ﬁbrils in a
process known as ‘‘seeding’’ (Fig. 1A).
Although there is no sequence homology or structural similarity
between the proteins that form amyloid, all amyloid deposits share
common characteristics. Amyloid ﬁbrils are typically unbranched,
5–10 nm in width, variable in length, polymorphic, and form a
cross b-sheet structure. This structure is deﬁned by perpendicular
orientation of the individual polypeptide chains to the long axis of
the ﬁbril; with the interchain hydrogen bonds aligned parallel to
Table 1
Common pathological amyloidoses and their major protein components.
Amyloidosis Disease Amyloidogenic Protein Deposition Type
Alzheimer’s Disease; Inclusion-body myositis; Down’s syndrome; Cerebral b-amyloid
angiopathy
Amyloid-b peptides (1–40 and 1–42) Neurodegenerative
Hereditary cerebral haemorrhage with amyloidosis Mutants of Amyloid-b peptides Neurodegenerative
Huntington’s disease (HD) Autosomal dominant mutation of human huntingtin
leading to expanded polyglutamine inserts
Neurodegenerative
Parkinson’s Disease and other synucleinopathies a-Synuclein Neurodegenerative
Familial amyotrophic lateral sclerosis (ALS); also known as motor neuron disease or Lou
Gehrig’s disease
Mutations in Superoxide dismutase (SOD1); TDP-43
and FUS/TLS
Neurodegenerative
Serpinopathies Mutations in members of the serine protease
inhibitor or serpin superfamily of proteins (Serpins)
Neurodegenerative
or Local
Bovine spongiform encephalopathies (BSE or Mad Cow disease); Creutzfeldt-Jakob
disease
Prions in the Scrapie form (PrpSc) Neurodegenerative
Intracytoplasmic neuroﬁbrillary tangles; Tauopathies; Alzheimer’s Disease Tau protein Neurodegenerative
Icelandic hereditary cerebral amyloid angiopathy (CAA); also known as hereditary
cyctatin C amyloid angiopathy
Mutant of cystatin C Neurodegenerative
Familial British dementia ABri polypeptide (ABriPP) Neurodegenerative
Familial Danish dementia ADan polypeptide (ADanPP) Neurodegenerative
Type 2 diabetes; pancreatic islet amyloidosis Amylin, also known as Islet Amyloid Polypeptide
(IAPP)
Local
Aortic medial amyloidosis Medin (a fragment of lactadherin) Local
Atrial amyloidosis Atrial natriuretic factor Local
Medullary carcinoma of the thyroid (MTC) Pro-calcitonin Local
Injection-localized amyloidosis Insulin Local
Critical illness myopathy (CIM) Hyperproteolytic state of myosin ubiquitination Local
Lichen amyloidosis Keratins Local
Restrictive amyloid heart; also known as cardiac amyloidosis, amyloid cardiomyophathy
or ApoA-I amyloidosis
Apolipoprotein A-I (Apo-A1) Local or Systemic
Cataract Crystallin family of proteins Local
Pituitary prolactinoma Prolactin Local
Pulmonary alveolar proteinosis (PAP) Pulmonary surfactant protein C Local
Familial amyloid polyneuropathy (FAP); Familial amyloid cardiopathy (FAC); Senile
systemic amyloidosis (SAA)
Transthyretin (TTR) Systemic
Familial amyloidosis of Finnish type (FAF) Fragments of gelsolin mutants Systemic
Amyloid light chain (AL) amyloidosis; also known as Primary systemic amyloidosis (PSA) Immunoglobulin light chains Systemic
Amyloid heavy chain (AH) amyloidosis Immunoglobulin heavy chains Systemic
Dialysis-related amyloidosis b2-microglobulin (b2m) Systemic
Corneal amyloidosis associated with trichiasis Variation of lactoferrin (LF) Local
Hereditary lattice corneal dystrophy Mainly C-terminal fragments of kerato-epithelin Local
AA amyloidosis or Secondary amyloidosis (associated with inﬂammatory disorders such
as tuberculosis, rheumatoid arthritis, bronchiectasis, ulcerative colitis, Crohn’s disease,
renal cell carcinoma, ankylosing spondylitis, nephritic syndrome, chronic
osteomyelitis, Hodgkin disease, familial Mediterranean fever)
Serum amyloid A (SAA) protein Systemic
Cerebral autosomal dominant arteriopathy with subcortical infarcts and
leukoencephalopathy (CADASIL)
Mutations in the Notch3 gene Neurodegenerative
or Systemic
ApoA-II amyloidosis Apolipoprotein A-II (ApoA2) Systemic
ApoA-IV amyloidosis N-terminal fragment of apolipoprotein A-IV (ApoA4) Systemic
Fibrinogen amyloidosis Variants of ﬁbrinogen a-chain Systemic
Lysozyme amyloidosis Mutants of lysozyme Systemic
Fig. 1. Amyloid formation by IAPP. (A) Schematic diagram of amyloid formation (solid blue curve). During the lag phase monomers associate to form oligomeric species
which then assemble to nucleate an exponential growth phase. Secondary nucleation and off-pathway steps such as formation of amorphous aggregates are omitted for
clarity. Amyloid formation can be accelerated by the addition of small amounts of preformed ﬁbrils (dashed red curve). (B) The primary sequence of human IAPP. The peptide
has a free N-terminus, an amidated C-terminus and an intramolecular disulﬁde bond between residues 2 and 7.
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compact tertiary structure in their unaggregated state, or they can
originate from ‘intrinsically disordered polypeptides’ that fail to
adopt compact tertiary structures in their soluble native state [4].
Amyloid formation from a folded precursor normally involves global
or local unfolding to an aggregation prone state, while intrinsically
disordered proteins can aggregate directly from their native ensem-
ble. Well studied examples of globular proteins that form amyloid
include b2-microglobulin, transthyretin (TTR) and mutants of hu-
man lysozyme. Stabilization of the native fold can prevent amyloid
by this class of proteins; this is the basis of the ﬁrst clinically ap-
proved, rationally designed, small molecule anti-amyloid agent
[5]. Ab, a-synuclein, and IAPP are important examples of intrinsi-
cally disordered polypeptides that form amyloid in vivo [2,6].
Amyloidosis diseases can be divided into three broad classes:
neurodegenerative, systemic and local amyloidosis [7]. In neurode-
generative diseases, amyloids are deposited in the brain and spinal
cord. Important examples of this class include AD, PD and Hunting-
ton’s disease (HD). In systemic amyloidoses, such as in the case of
amyloid light-chain (AL) amyloidosis, aggregation occurs in multi-
ple organs and tissues. A subset of systemic amyloidoses includes
lysozyme amyloidosis; senile systemic amyloidosis; familial trans-
thyretin-associated amyloidosis, which arises from deposition of
wild-type or one of more than 50 mutated forms of TTR; and dis-
eases of chronic inﬂammation, in which an N-terminal fragment
of the acute phase protein serum amyloid A (SAA) forms amyloid
deposits. In the non-neurological, localized amyloidoses, deposi-
tion of amyloid occurs in one target organ, usually proximal to
the production site of the amyloidogenic peptide. Important exam-
ples of this third class include amyloid formation by the crystallins
associated with cataract; atrial amyloid, caused by atrial natri-
uretic factor; and islet amyloidosis in T2D. The association be-
tween amyloid formation and disease pathogenesis is common
for all amyloidoses and the cytotoxic properties of amyloidogenic
peptides may be similar [8].
2. IAPP is one of the most amyloidogenic sequences known
2.1. Biosynthesis of IAPP
IAPP is synthesized as an 89 residue pre-prohormone. Removal
of the 22 residue signal sequence leads to the 67 residue pro-IAPP,
which is further processed in the Golgi and in the insulin secretory
granule to the 37 residue mature hormone [9,10]. Additional post
translational modiﬁcations include formation of an intramolecular
disulﬁde bridge between residues 2 and 7, and amidation of the C-
terminus (Fig. 1B). Mature IAPP is stored in the insulin secretory
granule at a ratio of 1:50 to 1:100 relative to insulin and is co-se-
creted with insulin [11].
IAPP is also subject to spontaneous, non-enzymatic, post-trans-
lational modiﬁcations that may impact its function and its ten-
dency to aggregate. For example, the human polypeptide
contains six chemically liable Asn residues which can undergo
spontaneous deamidation to yield Asp or iso-Asp residues. This
modiﬁcation results in the replacement of a neutral amide side
chain with a carboxyl group and will lower the net charge of hu-
man IAPP at physiological pH, and presumably decrease its solubil-
ity. Deamidation of human IAPP accelerates amyloid formation
in vitro, but its role in vivo is not understood [12].
2.2. The primary sequence of IAPP correlates with in vivo
amyloidogenicity
IAPP is a member of the calcitonin like family of polypeptides
and has been found in all animals studied, although not all species
form amyloid [13,14]. Mice and rats do not develop islet amyloid,but cats, non-human primates and humans do. The human poly-
peptide is extremely amyloidogenic in vitro, while rat IAPP is
not, even though the two polypeptides differ at only six positions.
Notably, rat IAPP contains three proline residues within the 20–29
sequence and these are believed to be responsible for its inability
to form amyloid. Much attention has been focused on the sequence
within the 20–29 region and the role it plays in controlling amyloid
formation. This portion of the polypeptide chain is considered to be
one of the major determinants of the ability of IAPP variants to
form amyloid. The characterization of designed variants of IAPP
support this conjecture; analogs of IAPP which contain prolines
or N-methylated residues at other positions within the 20–29 seg-
ment are considerably less amyloidogenic than wild type human
IAPP [15–17]. Proline and N-methyl amino acids are well known
to disrupt b-sheets. There is one known mutation in vivo within
this region, a Ser20Gly substitution, which enhances amyloid for-
mation [18,19]. While there is a strong correlation between the pri-
mary sequence of the 20–29 segment and in vitro
amyloidogenicity, mutations outside of this region can abolish
amyloid formation, indicating that it cannot be the sole factor con-
trolling IAPP’s amyloidogenicity [20–22]. For more information
about the biophysics and the sequence determinants of IAPP amy-
loid formation the reader is referred to the accompanying article by
Cao. et. al. in this issue.
2.3. Physiological function of IAPP
The physiological roles of IAPP are receptor mediated. The IAPP
receptor is formed from a complex of the calcitonin receptor with a
receptor activity modifying protein (RAMP) [23,24]. IAPP binds the
calcitonin receptor (CTR) in the absence of RAMPs, but the afﬁnity
is low. The afﬁnity of IAPP for the CTR-RAMP complex is higher,
with an IC50 reported to be on the order of 8 nM for the CTR–
RAMP-1 complex [25]. Six different subtypes of the IAPP receptor
are generated by different combinations of the two splice variants
of the calcitonin receptor with different RAMPs, but the distribu-
tion of the subtypes is not fully characterized [24,25].
Circulating concentrations of IAPP have been reported to be be-
tween 3–5 picomolar in rats, rising to 15–20 picomolar with in-
creased blood glucose levels [26]. However these values are
unlikely to be relevant to amyloid formation since IAPP is stored
at a much higher level in the insulin secretory granule, between
500 micromolar to several millimolar. This implies that the local
concentration of IAPP after release from the granule will be tempo-
rarily much higher than the circulating concentration.
The normal physiological roles of adaptive IAPP are not com-
pletely understood in humans, but studies in rodent models show
that IAPP is involved in the suppression of satiety and adiposity, as
well as the regulation of glucose homeostasis via inhibition of glu-
cose-stimulated insulin secretion (GSIS), gastric emptying, sup-
pression of glucagon release, vasodilatation, and the excretion of
calcium, potassium and sodium [26–35]. IAPP’s anorectic effect ap-
pears to be mediated mainly at the area postrema (AP) of the CNS.
Several recent reviews provide a critical and in depth examination
of the physiological roles of IAPP [26–29,34,35].
3. IAPP impacts T1D, T2D and islet cell transplantation
Amyloid accumulates in the pancreatic Islets of Langerhans in
the majority of individuals with T2D. Pancreatic amyloid deposits
were ﬁrst described more than 100 years ago, but the protein com-
ponent was not identiﬁed until much later when, in 1987 two
groups independently isolated a 37 residue polypeptide from
ex vivo samples of pancreatic amyloid [36–38]. Interest in islet
amyloid has undergone a resurgence in the last ten years with
the realization that b-cell dysfunction and the loss of b-cell mass
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tion is attributed to several factors, including islet inﬂammation,
glucolipotoxicity, accumulation of cholesterol and islet amyloid
formation [40–43].
Amyloid deposition is also an important factor in the failure of
islet cell transplants, and correlates with graft failure [44–46]. IAPP
amyloid forms rapidly upon transplantation of human islets into
nude mice and occurs before the recurrence of hyperglycaemia;
this is correlated with the loss of b-cells [44,45]. Islet amyloid
has been detected in transplanted human islets in a patient that
suffered islet graft failure [46]. Conversely, prevention of amyloid
formation by transplantation of porcine islets prolongs islet graft
survival [47].
In T2D, formation of islet amyloid by IAPP is a signiﬁcant prob-
lem and the clinical goal is to inhibit amyloidosis-induced toxicity.
The situation is different in type 1 diabetes (T1D); here the issue is
a lack of production of adaptive IAPP. IAPP is produced and re-
leased with insulin by pancreatic b-cells, thus it is absent in T1D,
as is insulin. The absence of physiologic concentrations of IAPP in
T1D and late stage T2D may have deleterious effects, motivating
the development of non-toxic bioactive analogs of human IAPP
for the clinical goal of hormone replacement therapy, as is done
with insulin. One analog has been approved as an adjunct for insu-
lin therapy for the treatment of diabetes and its administration is
reported to improve glycemic control. In contrast, there are no clin-
ically approved inhibitors of pathologic IAPP amyloid formation
indicated for T2D [48]. The nature of toxic species produced during
IAPP amyloidosis is not known, making it difﬁcult to design thera-
peutics that target the pathological form of the polypeptide. Cur-
rently, drug design aimed at preventing amyloid formation is an
active area of research.
3.1. Islet amyloid includes other components which may inﬂuence the
kinetics of amyloid formation and ﬁbril stability
In vivo, amyloid formation takes place in a heterogeneous envi-
ronment with the potential for interactions with molecules of the
extracellular matrix and with membranes, as well as with other
factors. Like other amyloid deposits, islet amyloid contains serum
amyloid P component (SAP), apolipoprotein E (apoE), and the hep-
aran sulfate proteoglycan (HSPG) perlecan [49–52]. There is a well
documented correlation between the e4 allele of the apolipopro-
tein E gene (apoe4) and AD [53]. The e4 allele plays an important
role in AD and has more widespread effects than any other genetic
factor that has been implicated in sporadic, late-onset AD. Studies
with apoE knockout mice have shown that this is not the case for
T2D [51]. Interactions between SAP and IAPP also do not appear
to play a role in amyloid deposition, but interactions with the gly-
cosaminoglycan (GAG) component of HSPGs might. GAG chains of
HSPGs have been shown to signiﬁcantly accelerate amyloid forma-
tion by IAPP and partially processed forms of pro-IAPP in vitro [54].
One model for IAPP amyloid formation in vivo assigns an impor-
tant role to the interaction of incorrectly processed proIAPP with
perlecan [55]. Perlecan is a component of the extracellular matrix
and is associated with islet amyloid. A fraction of the IAPP that is
secreted in T2D is incompletely processed and includes the N-ter-
minal ﬂanking peptide. Impaired processing leads to increased
amyloid [56,57], and the processing intermediate, denoted here
as IAPP-Npro, is found in islet amyloid. IAPP-Npro is less amyloido-
genic in solution than mature IAPP, but it interacts more effectively
with GAGs. Interactions with model GAGs signiﬁcantly enhance
the rate of in vitro amyloid formation by IAPP-Npro and the result-
ing ﬁbrils are able to seed amyloid formation by fully processed
IAPP [58]. Hence release of increased amounts of incorrectly pro-
cessed IAPP-Npro which bind to GAGs could generate a high local
concentration of the polypeptide and initiate amyloid formation.These deposits might recruit mature IAPP and additional IAPP-
Npro. Are interactions with GAGs important in vivo? The answer
is not known, but over-expression of heparanase inhibits amyloid
formation in a transgenic mouse that over-expresses IAPP, and
the inhibition of GAG synthesis in cultured islets has been demon-
strated to reduce amyloid deposition [59,60].
Binding of HSPGs to amyloid deposits could inﬂuence their sta-
bility and their clearance. Salts accelerate IAPP amyloid formation
and also stabilize IAPP ﬁbrils by reducing electrostatic repulsion
[61,62]. The polyanionic GAG chains of HSPGs could be even more
effective than simple salts since the spacing of the negative charges
in GAGs can match the spacing of the positively charged sites in
amyloid ﬁbrils [54]. The effect of GAGS on IAPP amyloid stability
and on the clearance of islet amyloid is a largely unexplored area.
3.2. The initiation site of islet amyloid formation is controversial
Determining if islet amyloid originates intracellularly or extra-
cellularly is important because it will directly impact therapeutic
approaches. The location of the initial site of islet amyloid deposi-
tion in vivo is currently controversial [27,63,64]. Amyloid deposits
found in T2D appear to be extracellular and initial histological
studies with rodent models argue in favor of an extracellular ori-
gin. Transgenic rodent models that over-express human IAPP are
consistent with an intracellular origin [63]. In contrast, work with
a cultured islet model is consistent with an extracellular origin of
islet amyloid [64]. That study showed that the secretion of IAPP
is an important factor in islet amyloid formation and b-cell toxicity.
The effect of reagents that increased IAPP secretion, but did not in-
crease the amount of IAPP produced, were used together with re-
agents that inhibited IAPP secretion, but maintained the level of
production of IAPP. Increasing secretion increased amyloid forma-
tion and toxicity, while inhibiting secretion reduced amyloid for-
mation and toxicity [64]. The conﬂicting results may be related
to the level of IAPP produced and to the techniques used in the
detection of amyloid [27,63–65].
4. Mechanisms of toxicity in other amyloidosis-potential
lessons for islet amyloidosis
A range of mechanisms has been proposed for the general toxic
effects of amyloidosis, however, the exact mechanisms of cell
death are still not completely clear. In some cases, amyloid ﬁbril
deposits physically disrupt tissue architecture and lead to organ
dysfunction, however, in most cases, activation of multiple over-
lapping cellular mechanisms and downstream signaling pathways
have been proposed to lead to disease pathogenesis. These include
receptor-mediated interactions and non-receptor mediated
phenomena.
Non-receptor based mechanisms have primarily focused on
membrane disruption and permeabilization by soluble oligomers
and amyloid ﬁbrils. Membrane disruption leads to an increase in
intracellular Ca2+ and has been shown to activate several patho-
genic pathways, including production of reactive oxygen species
(ROS) [66], altered signaling pathways [67,68] and mitochondrial
dysfunction [69]. Membrane permeabilization by amyloid oligo-
mers may also induce an oxidative stress response in cells
[66,70]. Permeabilization of mitochondrial membranes by amyloid
oligomers and the accumulation of Ca2+ in the matrix of mitochon-
dria lead to an increase in ROS production, cytochrome C release
and apoptosis [71,72]. ER stress has also been proposed to contrib-
ute to cytotoxicity [73].
Receptor-mediated mechanisms of toxicity include FAS (also
known as APO-1, APT or CD95), p75NTR (p75 neurotrophin recep-
tor) and RAGE (receptor for advanced glycation end products). In
particular, FAS and p75NTR have been investigated in IAPP and
Fig. 2. Physiological and pathophysiological effects of IAPP. According to this scheme, amyloidosis by adaptive IAPP leads to the production of cytotoxic species. The toxic
species of IAPP may form either intracellularly or extracellularly, leading to a series of parallel, overlapping and potentially additive or synergistic pathogenic pathways.
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dogenic species of Ab1–40 and Ab1–42, serum amylin A (SAA) and
prion-derived peptide, among others [76]. RAGE was originally
named for its ability to bind advanced glycation end products
(AGEs), but is now recognized as a multi-ligand pattern recognition
receptor with several classes of ligands including amyloid forming
polypeptides and proteins. RAGE not only elicits signaling path-
ways that lead to inﬂammation and apoptosis, but is also involved
in internalization of bound amyloidogenic ligands. RAGE-Ab inter-
actions have received prominence [76–78]; however, the role of
RAGE in islet amyloidosis has not been investigated.
Upregulation of autophagy has been recognized as a common
protective response to the accumulation of toxic amyloidogenic
aggregates in degenerative diseases [79–82]. However, autophago-
cytosis and lysosomal degradation of misfolded amyloidogenic
polypeptides and proteins is not entirely successful as accumula-
tion of amyloidogenic aggregates also leads to autophagy-medi-
ated lysosomal dysfunction and cell death [80,81].
Chronic inﬂammation may be an important contributing factor
to amyloidosis protein toxicity as it is frequently observed in local
and systemic amyloidosis diseases [83–85]. In neurodegenerative
diseases, such as AD, PD and HD, activation of microglia [86] and
pro-inﬂammatory processes (e.g. production of cytokines, chemo-
kines, nitric oxide (NO), ROS, and arachidonic acid metabolites)
can lead to oxidative stress, mitochondrial dysfunction and neural
toxicity [87–90]; however, the exact mechanisms of cell death are
controversial. Ab-induced activation of NF-kappaB, a potent imme-
diate-early transcriptional regulator of numerous proinﬂammatory
genes, has been shown to be stimulated by ROS formation in pri-
mary neurons derived from AD patients [91]. Activation of the
inﬂammasome protein complex by misfolded protein aggregates
has also been implicated in the pathogenesis of several amyloidosis
diseases such as AD and ALS, providing a common mechanism of
IL-1b cytokine production in these diseases [92].
Amyloid oligomers, which precede mature ﬁbrils, have been
implicated, albeit indirectly, in the pathogenesis of several dis-
eases, including AD, AL and TTR amyloidosis in vitro and in vivo;
and have been shown to trigger oxidative stress and activation ofapoptotic pathways [93–96]. The identity and nature of the speciﬁc
toxic species has not been addressed for islet amyloidosis.
Disease-speciﬁc events and pathways characterize amyloidoses.
Mutations that lead to the destabilization, unfolding and/or mis-
folding of proteins, are commonly associated with inherited dis-
eases. Mutations in proteins can also enhance the
amyloidogenicity of polypeptides and proteins resulting in acceler-
ation or increase in the formation of toxic amyloidogenic species.
Other disease-speciﬁc mutations can occur in genes that do not en-
code proteins that accumulate as amyloids, but rather impact the
production of amyloidogenic proteins. Examples include the pre-
senilins in AD and parkin in PD. These mutations can have the ef-
fect of increasing the concentration of aggregation prone proteins
and polypeptides. Presenilin mutations alter the proteolytic pro-
cessing of APP, leading to an increase in the more aggregation
prone Ab-42 isoform [97]. Covalent modiﬁcation of proteins, such
as oxidation, glycation and racemization can also promote unfold-
ing or mis-folding and may contribute to amyloid formation [95].
These common pathological mechanisms in amyloidogenic dis-
eases may stem from common properties that are shared among
toxic amyloidogenic species [8,95,96]. Ongoing efforts to elucidate
the mechanisms of cytotoxicity and tissue damage by other amy-
loid proteins may ultimately redirect therapeutic efforts in islet
amyloidosis.
5. Mechanisms of IAPP-induced b-cell toxicity in islet
amyloidosis
A subset of the mechanisms described above has been investi-
gated in the context of islet amyloidosis. Cell membrane permeabi-
lization or disruption by IAPP aggregates has been suggested to be
a mechanism of toxicity. Other mechanisms of IAPP toxicity in-
clude localized islet inﬂammation, defects in autophagy, ER stress,
as well as receptor-mediated mechanisms involving FAS and the
activation of downstream signaling pathways such as cJUN N-ter-
minal kinase (JNK). The available data suggest that IAPP exerts
its toxic effects on b-cells by multiple mechanisms. Several of these
overlap and share common signaling pathways (Fig. 2).
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in cell culture and in isolated human islets [65,98–101]. The path-
ways that lead to IAPP induced b-cell apoptosis are not yet fully
elucidated, although there is a growing body of literature and pro-
gress is being made [102,103].
It has been proposed that IAPP might exert non-speciﬁc cyto-
toxicity by permeabilizing cell surface membranes [104,105].
Numerous studies have demonstrated clustering of IAPP amyloid
ﬁbrils on or near membranes in vivo, and exogenous IAPP disrupts
cell membranes in vitro. The ability of IAPP to induce ion leakage
depends on the lipid composition of the membrane and the ratio
of lipid to peptide examined. An important caveat may be that
most of the in vitro membrane model systems employed in bio-
physical studies of membrane leakage utilize much higher frac-
tions of anionic lipids, and very different types of lipids than
those found innately in b-cells [106]. These membrane mimetics
lack cholesterol and gangliosides, which have been shown to play
a role in mediating IAPP clearance and membrane interactions
[107]. Studies have shown that IAPP variants that are not toxic to
b-cells in vivo have the ability to disrupt some of these in vitro
model membrane systems. Permeabilization and loss of membrane
integrity by IAPP may indeed be one mechanism of toxicity, partic-
ularly at high peptide concentrations, however, caution should be
taken when extrapolating from studies that employ non-physio-
logical model membranes and peptide concentrations to the more
complicated situation in vivo. More multifarious model mem-
branes are now being employed and are expected to provide new
mechanistic insights under more physiologically relevant condi-
tions [106].
Other proposed mechanisms of IAPP-induced b-cell death in-
clude defects in autophagy, local inﬂammation, mitochondrial dys-
function and receptor-mediated mechanisms linked to oxidative
stress, cytokine production and activation of signaling cascades
leading to apoptosis [73,102,103,108–117]. These toxic mecha-
nisms have been shown to be activated by either intracellular or
extracellular aggregates. The pro-apoptotic JNK pathway mediates
b-cell apoptosis in cultured cells and in islets exposed to high con-
centrations of IAPP, and has recently been shown to become upreg-
ulated in response to endogenous IAPP amyloid formation [103]. In
b-cells, JNK becomes activated by a range of events leading to cel-
lular stress, including ER stress, ROS formation and oxidative
stress, increases in glucose concentration and the production of
pro-inﬂammatory cytokines. Similar downstream signaling path-
ways have also been found to become activated in both the intrin-
sic (Bim) and extrinsic (Fas, Fadd) pathways. Interaction of either
endogenous or exogenous IAPP aggregates with FAS, also known
as the death receptor, leads to caspase 3 activation, while deletion
of Fas protects b-cells from IAPP toxicity [74]. These studies are
supported by in vivo experiments that demonstrate that inhibition
of caspase 3 protects b-cells from IAPP-induced b-cell apoptosis
[118]. The downstream signaling pathways that regulate b-cell
death in response to IAPP amyloidosis are not fully characterized,
and more work is needed to understand how many of these path-
ways intertwine and overlap, and whether these intracellular con-
sequences are triggered by interactions with cell surface receptors
and/or membrane disruption.
Defects in autophagy have been shown to play a role in amyloi-
dosis diseases and have been proposed to be a factor in IAPP toxic-
ity. Chaperone-mediated autophagy and macroautophagy ensure
synthesis of cellular components, recycle damaged or dysfunc-
tional organelles, and clear ubiquitinated proteins. Studies have
shown that activation of autophagy protects b-cells from IAPP-in-
duced apoptosis, while inhibition of autophagy-lysosomal diges-
tion promotes IAPP toxicity [110]. Over expression of IAPP in b-
cells, before the development of hyperglycemia, has been shown
to impair autophagy [110,115]. Thus, impairment in autophagycould lead to the build up of toxic aggregates and promote b-cell
death.
Local islet inﬂammation induced by toxic forms of IAPP may
play a role in b-cell dysfunction and death via activation of pro-
inﬂammatory responses [112,114]. IAPP has been shown to acti-
vate inﬂammasomes, which are multi-protein caspase activating
complexes that have been implicated in metabolic disease. Inﬂam-
masome activation triggers signaling cascades leading to the pro-
duction of pro-inﬂammatory cytokines such as Interleukin-1b (IL-
1b) [112]. IL-1b has been reported to be a mediator of IAPP-induced
b-cell toxicity, however the exact source(s) of IL-1b production
associated with islet amyloidosis in vivo is still an open question.
Defects in endoplasmic reticulum associated protein degrada-
tion (ERAD), unfolded protein response (UPR) and ER stress have
been reported to induce b-cell death by IAPP aggregates produced
both intracellularly and extracellularly [108,109,116,117]. In the
case where toxicity arises from intracellular aggregate formation,
ProIAPP and not mature IAPP may be the deleterious species, as
proIAPP miss-processing has been shown to occur in diabetes
and post-translational modiﬁcation is completed in the Golgi and
insulin secretory granules [56,57]. The exact role of ER stress in
IAPP-induced b-cell dysfunction in vivo is currently not well
understood. Studies using transgenic animal models that signiﬁ-
cantly overexpress IAPP support a role for ER stress, while no ER
stress was detected in cultured islets expressing lower levels of
IAPP [111].
One of the major unresolved issues in the ﬁeld of IAPP biology is
the difﬁculty in differentiating between the functional and toxic
forms of the polypeptide, making it difﬁcult to determine whether
the outcome of a particular experiment is relevant to the physio-
logical or pathophysiological situation. This problem is com-
pounded by the large variation in the methods used to prepare
IAPP by different workers. Small variations in peptide concentra-
tion, residual buffers and co-solvents can potentially alter peptide
secondary structure, affecting stability, aggregation kinetics and
potentially activation of off-target cellular stress responses. Cau-
tion should be applied when interpreting studies that use unchar-
acterized IAPP for in vitro or ex vivo investigations. Structural and
biochemical characterization of amyloidogenic polypeptides and
proteins is traditionally carried out by specialized spectroscopic
techniques primarily utilized by biophysicists and chemists. The
current gap between the disciplines of biology and biophysical
chemistry hinder research efforts, not only in the ﬁeld of islet amy-
loidosis, but in the study of amyloidosis diseases in general.
6. Therapeutic applications of IAPP for the treatment of
diabetes and obesity
IAPP is deﬁcient in individuals suffering from T1D and advanced
T2D. Co-administration of IAPP with insulin helps to normalize
ﬂuctuating glucose levels to a greater degree than is possible with
insulin alone [48,119]. However, the extreme amyloidogenicity of
human IAPP prevents its direct use as an adjunct to insulin therapy.
Consequently, a non-amyloidogenic analog of human IAPP, de-
noted as Pramlintide, which contains proline substitutions at the
same positions found in rat IAPP, was developed and has been ap-
proved by the FDA for use in the treatment of diabetes [48].
IAPP and IAPP analogs, such as Pramlintide, are also being ex-
plored for the treatment of obesity. Particularly exciting is the po-
tential of combining leptin and IAPP [120–122]. Leptin is an
adipokine that plays a major role in maintaining energy homeosta-
sis. The protein acts on the CNS to suppress appetite and alters
metabolism in peripheral tissue. Treatment of leptin deﬁcient
(ob/ob) mice with leptin has been shown to reduce food intake
and lead to weight loss. Individuals that lack functional leptin suf-
fer from extreme obesity, which can be reversed by treatment with
A. Abedini, A.M. Schmidt / FEBS Letters 587 (2013) 1119–1127 1125leptin [120]. Unfortunately, administration of exogenous leptin
does not lead to weight loss or reduction of food intake for obese
individuals who generate normal leptin, and the restoration of lep-
tin responsiveness in obese individuals is difﬁcult. This has led to
the concept of leptin resistant obesity, where obese individuals
are insensitive to high circulating concentrations of leptin. The
molecular mechanism of leptin signaling has been extensively
studied, although the origins of leptin resistance are not fully char-
acterized. Binding of the protein to its receptor stimulates Janus ki-
nase 2 (JAK2) and activates several pathways, including the
activator of transcription and signal transducer pathway (STAT3,
STAT5) which are important for the effects of leptin on body
weight [121–123]. Leptin-induced signaling is negatively con-
trolled by feedback systems that involve protein tyrosine phospha-
tase1B and suppression of cytokine signaling-3. The negative
feedback loop serves to prevent prolonged leptin receptor activa-
tion. Leptin-induced signaling has been recently reviewed [123].
Weight-lowering effects mediated by IAPP have been docu-
mented in obese rats and humans. IAPP and IAPP analogs have
been shown to reduce food intake without producing signs of con-
ditioned taste aversion or visceral illness [120,124]. Animal studies
with food-matched controls led to the notion that IAPP-induced
weight loss occurs via mechanisms similar to those found with en-
hanced leptin sensitivity [121,124]. Leptin and IAPP have been pro-
posed to affect energy homeostasis synergistically [120]. This
suggests that co-administration of leptin and IAPP might be bene-
ﬁcial. Administration of leptin to leptin resistant, diet-induced ob-
ese rats showed that leptin by itself is ineffective at inducing
weight loss. Treatment with IAPP alone led to modest loss in body
weight. However, the sustained use of the two polypeptides led to
signiﬁcant effects [120,122]. A recent report suggests that some of
the effects of IAPP and leptin might be additive rather than cooper-
ative [125]. In that study, administration of IAPP and leptin was
shown to activate extracellular-regulated kinase (ERK), STAT3,
AMP-activated protein kinase (AMPK) and the AKT signaling path-
ways in an additive, but not synergistic fashion, and the effects
were abolished by ER stress. The co-administration of IAPP and lep-
tin is still potentially an attractive therapeutic strategy in the ab-
sence of strong synergy since even additive effects could be
beneﬁcial. Other gastric satiety signals have also been shown to
have beneﬁcial effects when administered with leptin, and this is
an active area of research.
7. Perspectives, puzzles and future directions
Increasing evidence supports an adaptive role for IAPP in the
regulation of adiposity and energy homeostasis. Under normal cir-
cumstances, this neuropancreatic hormone is co-produced, co-
stored and co-secreted with insulin from b-cell secretory granules
into the circulation. In T1D and late stage T2D, lack of production of
adaptive IAPP may have deleterious consequences, while in early
T2D, overproduction and misprocessing of IAPP, along with other
factors, lead to islet amyloidosis and b-cell dysfunction and cell
death. Progress has been made in understanding the pathological
effects of IAPP amyloid formation in vivo, however many unan-
swered questions still remain. These include the mechanisms of is-
let amyloid formation and cytotoxicity in vivo and in vitro; the
initial site of amyloid deposition in vivo; the role of membranes
and HPSGs in vivo, the properties of the toxic species; and mecha-
nisms of clearance. Major hurdles that hinder progress include a
lack of physiologically relevant model systems for biophysical
studies, and the lack of detailed biophysical characterization of
IAPP prior to testing in biological assays. The latter is essential in
order to differentiate between adaptive and toxic forms of IAPP.
Bridging the gap between the disciplines will be important for
accurate interpretation of ex vivo biological and pharmacologicalstudies of IAPP using cultured cells and islets, as well as for identi-
ﬁcation of therapeutic targets and the design of pharmacological
agents for the treatment of islet amyloidosis.
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